platelet-derived growth factor receptor, or PDGFR, colony-stimulating factor 1 receptor, and c-KIT inhibitor. The company is currently conducting a Phase 3 clinical trial called the PROSERA Study ...

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

Coherus BioSciences, Inc.’s CHRS share price has surged by 6.33%, which has investors questioning if this is right time to sell.

SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect ...

AB Science SA (Euronext - FR0010557264 - AB) today reports its revenues for the year 2024 and provides an update on its activities. CLINICAL DEVELOPMENT KEY EVENTS DURING THE YEAR 2024 AND SINCE ...

Exicure has concluded subject enrolment in its ongoing randomised Phase II trial on GPC-100 (burixafor) in conjunction with ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Syndax Pharmaceuticals, Inc.’s SNDX share price has dipped by 16.84%, which has investors questioning if this is right time to buy.

Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK ...

an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication ...